PMC9342427_01
Before injection (A). After injection, nodules in the liver and spleen appeared hyper-enhanced in the arterial phase (B), washed out in the venous phase (C).
IJWH-14-957-g0001.jpg
PMC9342427_01_IJWH-14-957-g0001.jpg
f0001
The remaining liver parenchyma has hypo-enhanced areas (Figure 1).
Pelvic MRI showed multifocal lesions in the pelvis and femur.
IJWH-14-957-g0002.jpg
PMC9342427_01_IJWH-14-957-g0002.jpg
f0002
Pelvic magnetic resonance imaging (MRI) identified multifocal lesions in the pelvis and femur (Figure 2).
(A) Ultrasound-guided biopsy of the left liver; (B) selective embolization of the left hepatic artery by spongel.
IJWH-14-957-g0003.jpg
PMC9342427_01_IJWH-14-957-g0003.jpg
f0003
(A) Liver tumor tissues were rhombus-shaped (HE x 100); (B) liver tumor tissues were rhombus-shaped (HE x 200); (C) CD34-positive cells, Monoclonal Mouse Anti-Human CD34 Class II Clone QBEnd. (D) Factor VIII-positive cells, Rabbit Polyclonal Antibody. (E) ERG-positive cells, Rabbit Monoclonal Primary Antibody. (F) Ki-67 positive 10%, Monoclonal Anti-Human Ki-67 Antigen Clone MIB-1.
IJWH-14-957-g0004.jpg
PMC9342427_01_IJWH-14-957-g0004.jpg
f0004
There was a relatively high proliferation rate, stromal fibrous proliferation, and chronic inflammatory infiltrates (Figure 4A and B). Immunohistochemistry results revealed CD34 positivity (Figure 4C), factor VIII positivity (Figure 4D), ERG positive (Figure 4E), and Ki-67 positivity of 10% (Figure 4F).